Facilitated By

San Antonio Medical Foundation

News

  • Oncolytics' Chinese Partner Adlai Nortye Reports Interim Results Of Pelareorep-paclitaxel

    (RTTNews) - Oncolytics Biotech Inc. (ONCY)'s Chinese partner Adlai Nortye ... The company presented the data at the San Antonio Breast Cancer ...

  • Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical ...

    Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents ... Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium.

  • SABCS Data Solidifies Enhertu as Preferred Second-, Third-Line HER2-Positive Breast ...

    SAN ANTONIO – Two Phase II trials of Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan) confirmed the drug's benefit as a second- ...

  • DFS Improved With AIs vs Tamoxifen in HR+, HER2- Early Breast Cancer

    ... presented in a poster at the San Antonio Breast Cancer Symposium 2022. ... Disclosures: Some study authors declared affiliations with biotech, ...

  • Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines ... - BioSpace

    DAN-222 Phase 1 dose-escalation data at San Antonio Breast Cancer Symposium ... Dantari, Inc. is a clinical-stage biotechnology company developing ...